in ethanol). Column chromatography: Merck silica gel, grade 60, 230-400 mesh. Solvent proportions are indicated in a volume:volume ratio. All reactions were carried out with magnetic stirring unless otherwise stated and, in the case of air-or moisture-sensitive substrates and/or reagents, were handled in flame-dried glassware under argon or nitrogen. Organic extracts were dried with anhydrous MgSO4. Oxidant 2 was handled and stored in a glove box under nitrogen at < 0.1 ppm RH. [1] 4a, [2] 6-bromo-m-tyrosine, [3] 6-bromodopamine, [4] 4-(chloromethyl)-5-fluoroveratrol, [5] 4-(cyanomethyl)-5-fluoroveratrol, [6] 2-(2-pyridinyl)phenyl-2-nitrobenzenesulfonamide silver(I) salt, [2] 1,1′-(phenyl-λ3-iodandiyl)bis(4-dimethylaminopyridinium) bistrifluormethansulfonate, [7] iodosoben-pressure. The residue was taken up in EtOAc (100 mL) and the resulting solution was washed with H2O (740 mL), brine (230 mL), dried and concentrated under reduced pressure. Correct isotopic pattern.
2,

N-tert-Butyloxycarbonyl-6-bromodopamine:
A solution of Br2 (1.13 mL, 3.51 g, 21.99 mmol) in AcOH (25 mL) was added dropwise within 2 h to a vigorously stirred suspension of dopamine hydrochloride (4.17 g, 21.99 mmol) in AcOH (100 mL) and the reaction mixture was concentrated under reduced pressure. The dark-brown residue was taken up in toluene (50 mL) and volatiles were evaporated under reduced pressure (three times) to give a crude 6-bromodopamine hydrobromide [4] which was directly used for the next step without any further purification. Correct isotopic pattern.
2-Fluoro-4,5-dimethoxyphenethylamine hydrochloride: [10] TFA (2.51 mL, 3.74 g, 32.79 mmol)
was added dropwise to a stirred suspension of NaBH4 (1.24 g, 32.79 mmol) in THF (30 mL) under Ar over 10 min. Afterwards, a solution of 2-fluoro-4,5-dimethoxybenzonitrile [6] (0.63 g, 3.22 mmol) in THF (10 mL) was added via a cannula and the reaction mixture was stirred for further 16 h. Thereafter, the mixture was ice-cooled and quenched by the careful addition of water. The resulting mixture was concentrated under reduced pressure to give the residue which was extracted with CH2Cl2 (5×30 mL). The extract was washed with H2O (10 mL) and brine (2×20 mL), dried, filtered and concentrated under reduced pressure. The residue was dissolved in EtOAc (10 mL) and the resulting solution was treated with 2 M HCl in EtOAc (5 mL). The solution was evaporated to dryness under reduced pressure and the residual oil was taken in EtOAc (30 mL) and heated to reflux for a short time using a heat gun. After cooling to ambient temperature, the precipitate was collected by filtration. The filter cake was washed with EtOAc (10 mL) and dried to give the title compound (0.45 g, 59%) as a rose solid. 1 [11] A solution of 2-fluoro-4,5-dimethoxyphenethylamine hydrochloride (0.42 g, 1.78 mmol) in 48% HBr (4 mL) was heated under Ar at 140 C for 90 min. Thereafter, the reaction mixture was cooled to ambient temperature and placed in a refrigerator. After 3 h the 
6-Fluorodopamine hydrobromide (1c·HBr):
6.7 Hz, 2H), 1.54 (s, 18H), 1.43 (s, 9H). 13 C NMR (75 MHz, CDCl3) δ 158.1 (d, J = 244.5 Hz)
Ni-aryl complex 4c:
To 
Specific activity calculation
The specific activities (GBq/µmol) were calculated by dividing the radioactivity of the 18 F-labeled product by the amount of the unlabeled tracer determined from the peak area in the UV-HPLC chromatograms (λ=210 nm). The amounts of unlabeled compounds were determined from the UVabsorbance/concentration calibration curve. 
In vivo evaluation
All experiments were carried out in accordance with the EU directive 2010/63/EU for animal experiments and the German Animal Welfare Act (TierSchG, 2006) and approved by regional authorities (LANUV NRW).
Rat model of hemi-Parkinson's disease: Adult male Long Evans rats (Janvier, France) were used.
Rats were anesthetized (initial dosage: 5% isoflurane in O2/N2O (3:7), then reduction to 2.5%) and fixed in a stereotaxic frame. Body temperature was monitored rectally and was held constant at 37 °C using a heating pad. After removing skin and periosteuma, a small hole (approx. 1 mm in diameter) was drilled in the skull 1.2 mm lateral and 4.4 mm posterior from bregma, and the cannula of a Hamilton syringe was inserted 8 mm deep, measured from the level of the dura mater. 6-Hydroxydopamine hydrobromide (6-OHDA, Sigma Aldrich, contains ascorbic acid as stabilizer) (21 µg) in isotonic saline (3 µL) was slowly injected, and the cannula was left in place for 10 min. After retraction of the cannula, the burr hole was closed with bone wax and the skin wound was sutured.
Finally, carprofen for analgesia (Rimadyl®) (3 mg) was subcutaneously injected.
µPET-Imaging: PET measurements were carried out 6-8 weeks after 6-OHDA injection. Prior to the PET measurement animals were anesthetized (initial dosage: 5% isoflurane in O2/N2O (3:7), then reduction to 2%), and a catheter for tracer-injection was inserted into the lateral tail vein. Rats were placed on an animal holder (medres GmbH, Cologne, Germany), and fixed with a tooth bar in a respiratory mask. Dynamic PET scans in list mode were performed using a Focus 220 micro PET Thereafter a 10 min transmission scan was acquired using a 57 Co point source. Breathing rate was monitored with a Dasy Lab system 9.0 (DasyLab, Mönchengladbach, Germany) and kept around 60/min by adjusting the isoflurane concentration (1.5-2.5%). Body temperature was maintained at 37 °C by a feedback-controlled system (medres GmbH, Cologne, Germany). Following Fourier rebinning, data were reconstructed using an iterative OSEM3D/MAP procedure [13] including attenuation correction in two different ways: 1) 24 frames (6×30 s, 3×1 min, 3×2 min, 12×4 min) for compilation of striatal time activity curves. 2) 2 frames (2×30 min) for other VOI analyses.
Resulting voxel sizes were always 0.38×0.38×0.82 mm.
MR-Imaging:
To rule out gross structural brain anomalies and to provide individual templates for co-registration of the PET images, T2-weighted structural MR images were acquired. MRI scans were performed in an 11.7-T BioSpec animal scanner (Bruker BioSpin®) using a quadrature receive-only rat brain surface coil (Bruker BioSpin®) in combination with an actively decoupled, transmit-only quadrature resonator with 72 mm inner diameter (Bruker Biospin), fitting into the BFG-150/90-S14 combined gradient and shim set of 90 mm inner diameter (Resonance Research Inc., Billerica, MA, USA) with a maximum gradient strength of 745 mT/m. A T2-weighted sequence, rapid acquisition with relaxation enhancement (RARE) was used: RARE factor = 8, repetition time/effective echo time = 6500/32.5 ms, averages = 2, matrix size = 256256, FOV = 3.23.2 cm 2 , 58 slices, slice thickness = 0.5 mm, interslice spacing = 0.5 mm. The inhalation anesthesia procedure was the same as that used for the μPET scan. During scanning, body temperature was recorded and maintained at 37° using feedback water control (medres GmbH, Cologne, Germany); physiological parameters, in particular respiration rate, were monitored using DASYLab 9.0 (DasyLab, Moenchengladbach, Germany).
Imaging Data Analysis: MR-[Gauss filtered (2 mm FWHM)] and µPET-Images were manually co-registered using VINCI 4.04 software. [14] SUVs (%ID/g) were calculated by dividing the concentration of [ 18 F]FDOPA in the region of interest by the total injected dose (ID) and multiplying by 100.
To obtain time activity curves, an elliptical 10 mm 3 volume of interest (VOI) was placed over the intact striatum. Mean SUV values were extracted from each of the 24 frames, decay corrected, and plotted over time.
For other VOI analyses, the frame covering 30-60 min post injection was used. Two elliptical VOIs (17 mm 3 each) were placed in the left and right striatum, respectively, and a 90 mm 3 VOI was used for the cerebellum. Mean SUV values were used to calculate striatum-to-cerebellum and ipsi-tocontralateral striatal ratios.
